Answers are grounded in this paper and cite their sources.
Novartis has agreed to license Arvinas's protein-degradation prostate cancer drug ARV-766 . This clinical-stage candidate targets mutated androgen receptors that are thought to confer resistance to cancer drugs. Arvinas has also sold to Novartis its preclinical program that targets AR-V7, a variant androgen receptor that may also allow cancer cells to evade existing treatments. Arvinas will receive an up-front payment of $150 million, with the potential for $1 billion in milestone and royalty payments.
No takes yet. Share an insight, caveat, or question.
Sarah Braner (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: